CDC Releases Updated Recommendations for Treatment of Latent TB Infection
June 28, 2018 – 3HP for Latent TB Infection Treatment
CDC released updated recommendations for use of once-weekly isoniazid-rifapentine for 12 weeks (3HP) for treatment of latent tuberculosis (TB) infection. The updated recommendations support expanded use of an effective, shorter, treatment regimen to reach even more people with latent TB infection. The 3HP regimen can help remove current barriers to latent TB treatment for both patients and providers.
- Media Summary: Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
- MMWR: Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
- Fact Sheet: TB in the United States: A SnapshotCdc-pdf
- Latent Tuberculosis Infection Resources
Graphics:
These high-resolution, public domain images are ready to download and print in your publication. Click on a graphic to see it in high-resolution. For your convenience, we have included a table that contains the specific data from the report used to generate these charts. These images are in the public domain and are thus free of any copyright restrictions. As a matter of courtesy, we ask that the content provider be credited and notified of any public or private usage of an image.
View High Resolution Version
CDC’s updated recommendations for 3HP support expanded use of an effective and shorter treatment regimen to reach even more people with latent TB infection.
View High Resolution Version
The 3HP regimen can help remove current barriers to latent TB treatment for both patients and providers. By supporting a shorter treatment timeframe, offering the option for self-administration, and reducing treatment costs (estimated $400 for self-administered 3HP, compared to an estimated $18,000 to treat TB disease), treatment completion and cure of latent TB infection can be improved.
